Advancements in the Development of ADC-technology for Cancer Treatment
In an article published in Future Drug Discovery, Justyna Mysliwy, Bioconjugation Team Leader at Iksuda Therapeutics, writes about the de developments in the technology...
Growing Number of Major Medical Meetings Cancelled – AACR and Others...
The novel coronavirus, also known as COVID19, is prompting major medical societies and healthcare organizations to cancel conferences and events around the world.The decision...
Silverback Raises U.S. $78.5 Million to Advance SBT6050 into the Clinic...
Seattle-based Silverback Therapeutics™, a biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC™ drug conjugates targeting previously inaccessible disease pathways, confirmed that it has raised U.S. $78.5 million Series B financing an oversubscribed funding...
Modeling and Optimization of Antibody-drug Conjugate Production Using Process Intensified Solid-phase...
Research articleAbstract
Conventional solution-phase method currently employed for the production of Antibody-drug Conjugates (ADC) has certain drawbacks, which makes production inefficient and cost extensive process. In this study, we developed a rigorous cost model for...
Novel Treatments are a Positive Development for Patients with Metastatic Urothelial...
This week has brought welcome news to bladder cancer patients and their loved ones. Two drugs with great potential for combatting different types of...
FDA Accepts Resubmission of Biologics License Application for Sacituzumab Govitecan
Earlier today the U.S. Food and Drug Administration (FDA) confirmed that it has accepted Immunomedics' Resubmission of the Biologics License Application (BLA) for sacituzumab govitecan, also known as IMMU-132, for the treatment of metastatic...
